Abstract:Activation of Wnt/β-catenin signaling pathway in the tumor cells has been shown to promote cell proliferation and correlate with cancer progression. Therefore, dickkopf-1 (Dkk1), a soluble Wnt/β-catenin inhibitor, has been considered as a tumor suppressor. However, contradicting evidence demonstrated that high levels of circulating Dkk1 correlate with poor prognosis in various cancers. Although Dkk1 is best known to modulate bone remodeling, we recently reported that Dkk1 supports the growth of subcutaneous B16 melanomas by creating an immune-suppressive environment. However, the detailed mechanism by which Dkk1 alters anti-tumor immune responses remains to be elucidated. In this study, we used mice orthotopically injected with hormone-resistant luminal B, ER+ PyMT, EO771 and triple-negative 4T1 cell lines. We find that Dkk1 is upregulated in all models and its neutralization reduces tumor growth. To our surprise, Dkk1 was barely expressed by each tumor lines tested. However, we found elevated expression of Dkk1 in the bone by the osteoblasts (OBs) and in the breast tumor stroma by cancer-associated fibroblasts (CAFs), although at a much lower level compared to the OBs. To address the role of bone-derived versus tumor stroma-derived Dkk1 during tumor progression, we generated mouse models specifically deleting Dkk1 from OBs (OsxCre;Dkk1fl/fl), and from CAFs (Fsp1Cre;Dkk1fl/fl and aSMACreERT2;Dkk1fl/fl). To our surprise, all our mouse models reduced orthotopic PyMT tumor growth significantly, suggesting that Dkk1 could act both systemically and locally to modulate tumor progression. Interestingly, however, deletion of Dkk1 in the bone or in the CAFs did not appear to change the immune composition in the bone marrow, spleen, or at the tumor site. Next, we orthotopically injected PyMT cells into the severely immune-compromised NSG mice treated with anti-Dkk1 or IgG. Strikingly, Dkk1 neutralization did not reduce tumor growth in NSG mice, suggesting that Dkk1 modulates breast cancer growth by altering anti-tumor immune responses. Similar to mice with deletion of Dkk1 in the bone or in the CAFs, Dkk1 neutralization did not alter the percentage of the myeloid and lymphoid cell subsets or the activation status of T cells in bone marrow, spleen, or tumor site compared to IgG control mice. However, by IHC we observed that tumors from anti-Dkk1-treated mice or with deletion of Dkk1 in the CAFs had increased numbers of CD4+ and CD8+ T cells infiltrating the center of tumor mass while these immune populations remained at the edges of the tumors in control mice. In summary, we provide evidence that Dkk1 exerts local and systemic effects to promote tumor progression by modulating the infiltration of immune cells into the TME. Citation Format: Seunghyun Lee, Biancamaria Ricci, Roberta Faccio. Dickkopf-1 induces breast cancer progression by limiting T cell infiltration into the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr LB100.

Dickkopf-1 Inhibits Migration in Breast Cancer Cells via Upregulating nm23

Downregulation of Dickkopf-1 is Responsible for High Proliferation of Breast Cancer Cells Via Losing Control of Wnt/β-catenin Signaling

Silence of MACC1 Decreases Cell Migration and Invasion in Human Malignant Melanoma Through Inhibiting the EMT.

DKK1 inhibits breast cancer cell migration and invasion through suppression of β-catenin/MMP7 signaling pathway

Mir-145 Suppresses Breast Cancer Cell Migration by Targeting FSCN-1 and Inhibiting Epithelial-Mesenchymal Transition.

Dkk-1 Secreted by Mesenchymal Stem Cells Inhibits Growth of Breast Cancer Cells Via Depression of Wnt Signalling.

Dickkopf-1 Enhances Migration of HEK293 Cell by Beta-Catenin/e-cadherin Degradation.

Dickkopf-related Protein 2 Induces G0/G1 Arrest and Apoptosis Through Suppressing Wnt/β-catenin Signaling and is Frequently Methylated in Breast Cancer

Dickkopf-related protein 2 induces G0/G1 arrest and apoptosis through suppressing Wnt/β-catenin signaling and is frequently methylated in breast cancer.

Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients

Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma

Epigenetic Silencing of the WNT Antagonist Dickkopf 3 Disrupts Normal Wnt/β-catenin Signalling and Apoptosis Regulation in Breast Cancer Cells.

Dickkopf‐1 Expression is Down‐regulated During the Colorectal Adenoma–carcinoma Sequence and Correlates with Reduced Microvessel Density and VEGF Expression

Cancer-associated fibroblast-derived Dickkopf-1 suppresses NK cell cytotoxicity in breast cancer

Abstract LB100: Dickkopf-1 induces breast cancer progression by limiting T cell infiltration into the tumor microenvironment

Dickkopf-1-Promoted Vasculogenic Mimicry in Non-Small Cell Lung Cancer is Associated with Emt and Development of A Cancer Stem-Like Cell Phenotype

Proliferation and Migration Mediated by Dkk-1/Wnt/β-catenin Cascade in a Model of Hepatocellular Carcinoma Cells

CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells

The Biological Effects of Dickkopf1 on Small Cell Lung Cancer Cells and Bone Metastasis

Dickkopf-1: A Promising Target for Cancer Immunotherapy

Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer